Tag: tablets

Posted on

Immunotherapy Tablets For Dust Mite Allergy Reduce Asthma Risk – NPR


NPR

Immunotherapy Tablets For Dust Mite Allergy Reduce Asthma Risk
NPR
Immunotherapy tablets are starting to edge out shots as a treatment for allergies. And it looks like the pills can help reduce the frequency of asthma attacks, too. Scientists reported Tuesday that immunotherapy tablets for dust mite allergy reduced …
Spring is peak 'achoo' seasonThe Recorder
Tree love in the air; allergic, bewarePhilly.com
The shocking rise of adult allergies – and could you be at risk?Irish Mirror

all 5 news articles »

View full post on asthma – Google News

Posted on

Ajanta Pharma’s Generic Anti-Asthma Chewable Tablets Approved By US FDA – International Business Times


International Business Times

Ajanta Pharma's Generic Anti-Asthma Chewable Tablets Approved By US FDA
International Business Times
According to U.S. National Library of Medicine, Montelukast is used to prevent chest tightness, difficulty in breathing and wheezing and coughing caused by asthma. In addition, it is used to prevent the symptoms associated with seasonal allergies and …
Ajanta Pharma launches generic asthma treatment tablets in USEconomic Times
Ajanta Pharma launches generic asthma treatment tabletsMoneycontrol.com
Ajanta Pharma launches anti-asthma tablets in USMyiris.com

all 17 news articles »

View full post on asthma – Google News

Posted on

Ajanta Pharma launches generic asthma treatment tablets in US – Economic Times

Ajanta Pharma launches generic asthma treatment tablets in US
Economic Times
NEW DELHI: Ajanta Pharma has launched its generic Montelukast Sodium tablets used for treatment of asthma and seasonal allergies in the American market. Ajanta Pharma USA Inc, a subsidiary of the company today announced the launch of Montelukast …
Ajanta Pharma launches generic asthma treatment tabletsMoneycontrol.com
Ajanta Pharma launches anti-asthma tablets in USMyiris.com

all 7 news articles »

View full post on asthma – Google News

Posted on

A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK-Abello A/S, Originator or ALK HDM Tablets in Adult Subjects With Allergic Rhinitis and/or Atopic Asthma Induced by House Dust Mites (HDM)

Conditions:   Allergy;   Asthma;   Rhinitis
Interventions:   Drug: Mitizax;   Drug: Placebo
Sponsors:   Abbott;   Linical Co., Ltd;   Datamap
Recruiting – verified November 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Posted on

A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK-Abello A/S, Originator or ALK HDM Tablets (ALK HDM Tablets) in Adult Subjects With Allergic Rhinitis and/or Atopic Asthma Induced by House Dust Mites (HDM)

Conditions:   Allergy;   Asthma;   Rhinitis
Interventions:   Drug: Mitizax;   Drug: Placebo
Sponsors:   Abbott;   Linical Co., Ltd;   Datamap
Recruiting – verified November 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Posted on

Maintenance of Remission With Budesonide Effervescent Tablets vs. Placebo in Eosinophilic Esophagitis

Condition:   Eosinophilic Esophagitis
Interventions:   Drug: Budesonide effervescent 0.5mg tablet twice daily;   Drug: Budesonide effervescent 1mg tablet twice daily;   Drug: Placebo effervescent tablet twice daily
Sponsor:   Dr. Falk Pharma GmbH
Not yet recruiting – verified July 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Posted on

Jubilant Life gets USFDA nod for generic anti-asthma tablets – Economic Times

Jubilant Life gets USFDA nod for generic anti-asthma tablets
Economic Times
NEW DELHI: Drug firm Jubilant Life Sciences has received final approval from the US health regulator for generic Montelukast Sodium chewable tablets used in the treatment of asthma and to relieve symptoms of seasonal allergies. "The company has …
Jubilant Life Sciences gets ANDA nod for MontelukastMyiris.com

all 7 news articles »

View full post on asthma – Google News

Posted on

Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects

Condition:   Respiratory Disorders
Interventions:   Drug: Reference Montelukast;   Drug: Test 1 Montelukast;   Drug: Test 2 Montelukast
Sponsor:   GlaxoSmithKline
Not yet recruiting – verified December 2014

View full post on ClinicalTrials.gov: asthma | received in the last 14 days